ATM mutations in sporadic lymphoid tumours

被引:70
作者
Stankovic, T
Stewart, GS
Byrd, P
Fegan, C
Moss, PAH
Taylor, AMR
机构
[1] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[2] Birmingham Heartlands Hosp, Dept Haematol, Birmingham B9 5SS, W Midlands, England
关键词
ATM mutations; lymphoid tumours; ataxia telangiectasia;
D O I
10.1080/1042819021000002884
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with the autosomal recessive disorder ataxia telangiectasia (A-T) show the biallelic inactivation of the ataxia telangiectasia mutated (ATM) gene. A-T patients exhibit a predisposition to the development of a wide range of lymphoid tumours, suggesting that the ATM protein normally plays an important role in the prevention of both T and B cell malignancies. The ATM protein is a 370 kDa protein kinase implicated in the integration of different cellular responses to particular forms of DNA damage. Several recent studies have reported the possibility that the ATM gene can act as a tumour suppressor gene in non A-T individuals. Frequent ATM inactivation was confirmed in three sporadic lymphoid tumours of mature phenotype: T cell prolymphocytic leukaemia (T-PLL), B-cell chronic lymphocytic leukaemia (B-CLL) and mantle cell lymphoma (MCL). Here, we provide a summary of the published ATM mutations in sporadic lymphoid tumours, including our own study on the role of ATM mutations in the pathogenesis of sporadic B-CLL. The published results suggest possible differences in the origin, the nature and distribution of ATM mutations between sporadic B-CLL, MCL and T-PLL. While ATM mutations in mature B cell tumours (B-CLL and MCL) represent a mixture of missense and truncating errors distributed across the whole of the ATM coding sequence, mutations in sporadic T-PLL appear to be predominantly missense, clustering in the region encoding the PI-3 kinase catalytic domain of the protein. The reason for this difference is unclear, but the difference itself supports the notion that the pathogenesis of B and T cell tumours on an ATM deficient background might be different. In addition, in both B-CLL and MCL ATM mutation carriers have been reported, raising the possibility that ATM mutation carriers may have an increased risk of developing these tumours. The existence as well as magnitude of the risk, however, remains to be established. Furthermore, our own studies indicate that the presence of ATM mutations in sporadic B-CLL causes a distinctive defect in response to DNA damaging agents, offering a possible explanation for the poor response of ATM mutant tumours to standard treatment. Therefore, one of the future challenges will be to devise strategies to bypass the existing defect in response to DNA damage and activate apoptosis in ATM mutant sporadic lymphoid tumours.
引用
收藏
页码:1563 / 1571
页数:9
相关论文
共 51 条
[1]   Update on the biology of chronic lymphocytic leukemia [J].
Bannerji, R ;
Byrd, JC .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (01) :22-29
[2]   MUTATION DRIFT AND REPERTOIRE SHIFT IN THE MATURATION OF THE IMMUNE-RESPONSE [J].
BEREK, C ;
MILSTEIN, C .
IMMUNOLOGICAL REVIEWS, 1987, 96 :23-41
[3]   Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia [J].
Bevan, S ;
Catovsky, D ;
Marossy, A ;
Matutes, E ;
Popat, S ;
Antonovic, P ;
Bell, A ;
Berrebi, A ;
Gaminara, EJ ;
Quabeck, K ;
Ribeiro, I ;
Mauro, FR ;
Stark, P ;
Sykes, H ;
van Dongen, J ;
Wimperis, J ;
Wright, S ;
Yuille, MR ;
Houlston, RS .
LEUKEMIA, 1999, 13 (10) :1497-1500
[4]  
Bullrich F, 1999, CANCER RES, V59, P24
[5]  
CALIGARIS CF, 2000, REV CLIN EXP HAEMATO, V4, P5
[6]   ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances [J].
Camacho, E ;
Hernández, L ;
Hernández, S ;
Tort, F ;
Bellosillo, B ;
Beà, S ;
Bosch, F ;
Montserrat, E ;
Cardesa, A ;
Fernández, PL ;
Campo, E .
BLOOD, 2002, 99 (01) :238-244
[7]   Checkpoints: How to activate p53 [J].
Caspari, T .
CURRENT BIOLOGY, 2000, 10 (08) :R315-R317
[8]   THE HUMAN-IMMUNOGLOBULIN V-H REPERTOIRE [J].
COOK, GP ;
TOMLINSON, IM .
IMMUNOLOGY TODAY, 1995, 16 (05) :237-242
[9]   p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis [J].
Cordone, I ;
Masi, S ;
Mauro, FR ;
Soddu, S ;
Morsilli, O ;
Valentini, T ;
Vegna, ML ;
Guglielmi, C ;
Mancini, F ;
Giuliacci, S ;
Sacchi, A ;
Mandelli, F ;
Foa, R .
BLOOD, 1998, 91 (11) :4342-4349
[10]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847